Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men

scientific article published on 01 April 1995

Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199504063321403
P698PubMed publication ID7877648

P50authorPaul RidkerQ7153226
Meir J. StampferQ80164992
Charles H HennekensQ89527500
P2093author name stringMiletich JP
Lindpaintner K
Eisenberg PR
P433issue14
P407language of work or nameEnglishQ1860
P921main subjectthrombosisQ261327
myocardial infarctionQ12152
P304page(s)912-917
P577publication date1995-04-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleMutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
P478volume332

Reverse relations

cites work (P2860)
Q343884721998 ASHG presidential address. Making genomic medicine a reality
Q35024990A multilocus genotyping assay for candidate markers of cardiovascular disease risk
Q40718658A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction
Q34117782A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men.
Q33538903APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women
Q35169691Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women
Q36100026Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients
Q71154638Activated protein C and pulmonary embolism
Q26865139Activated protein C anticoagulant system dysfunction and thrombophilia in Asia
Q54167601Activated protein C resistance and graft occlusion after coronary artery bypass surgery
Q54150362Activated protein C resistance and the factor V Leiden mutation in children with thrombosis.
Q41248865Activated protein C resistance as a basis for venous thrombosis
Q41417615Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Q58320642Activated protein C resistance in childhood stroke
Q35298277Activated protein C resistance in patients with central retinal vein occlusion
Q54120223Activated protein C resistance in patients with peripheral vascular disease.
Q43632787Activated protein C resistance in young African American patients with ischemic stroke
Q41137636Activated protein C resistance: from phenotype to genotype and clinical practice.
Q91877901Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report
Q28361651American College of Medical Genetics consensus statement on factor V Leiden mutation testing
Q51546713An age-related decrease in factor V Leiden frequency among Polish subjects.
Q33893199An electrochemical detection scheme for identification of single nucleotide polymorphisms using hairpin-forming probes
Q78111674Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism
Q77299095Arterial thromboembolic events in patients with the factor V Leiden mutation
Q74597665Assessment of genetic markers for coronary thrombosis: promise and precaution
Q35602154Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies
Q35777683Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases
Q35894772Association of factor V gene polymorphism with arteriovenous graft failure
Q37273821Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations
Q54021331Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
Q50534991C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study.
Q54595795Characterisation of single nucleotide polymorphisms in sugarcane ESTs.
Q35103077Clinical and laboratory evaluation of thrombophilia
Q35291832Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors
Q71691177Clinical significance of the FV:Q506 mutation in unselected oncology patients
Q43587450Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis.
Q43633269Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases
Q38482800Decreased mortality of ischaemic heart disease among carriers of haemophilia
Q81584045Deep vein thrombosis
Q78171123Deep-vein thrombosis
Q45108556Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
Q33655220Diagnosis and management of inherited and acquired thrombophilias
Q33886973Diagnostic evaluation of stroke
Q34027225Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis
Q50854569Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation.
Q54079422Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Q34990662Effects of lipids on thrombotic mechanisms in atherosclerosis
Q86494328Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR)
Q35019234Elevated risk of thrombophilia in agenesis of the vena cava as a factor for deep vein thrombosis.
Q47889309Emerging risk factors for stroke: patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance
Q37723948Establishment of a model of spontaneously-running-Tokushima-shikoku rats with left atrial thrombosis
Q34065857Etiology and pathophysiology of stroke as a complex trait
Q34439986Evaluation of GenoFlow Thrombophilia Array Test Kit in its detection of mutations in Factor V Leiden (G1691A), prothrombin G20210A, MTHFR C677T and A1298C in blood samples from 113 Turkish female patients
Q73295929Evaluation of Hypercoagulable States
Q38471289Evaluation of role of factor V Leiden mutation in fatal pulmonary thromboembolism
Q47583371Evaluation of temperature gradient capillary electrophoresis for detection of the Factor V Leiden mutation: coincident identification of a novel polymorphism in Factor V.
Q54160830Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Q36253998Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation
Q47686776FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke
Q71807450Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism
Q44461414Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet disease
Q46136302Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Q36147640Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels
Q33543425Factor V Leiden mutation: a nursing perspective
Q33606504Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?
Q36600956Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Q74020811Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease
Q37041027Factor VLeiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease
Q44683596Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679.
Q73384826Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis
Q36539672Functional single nucleotide polymorphism-based association studies
Q73386872G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism
Q41245762General internal medicine update. Information clinicians and teachers need to know
Q53967904Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers.
Q44823742Genetic and acquired thrombotic factors in chronic hepatitis C.
Q52211005Genetic determinants of heritable venous thrombosis: genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations.
Q49289901Genetic thrombophilia in patients with retinal vascular occlusion
Q35532628Genetics and pulmonary medicine. 4. Pulmonary embolism
Q41725452Genetics of stroke--a review
Q22306331Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Q37274431Hematological diseases and stroke
Q28195599Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting
Q41615867Hemostatic risk factors in arterial thrombosis and atherosclerosis: the thrombin-fibrin and platelet-vWF axis
Q39405390Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium
Q77813840Heterozygosity for factor V Leiden and G20210A prothrombin genotypes in a patient with mesenteric vein thrombosis
Q73925175Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens
Q91672343High factor VIII levels and arterial thrombosis: illustrative case and literature review
Q33835022High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.
Q79293356Homozygous factor V Leiden mutation in a patient with traumatic leg ulceration
Q47889299Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis
Q33374342Hypercoagulability syndromes: what the dentist needs to know
Q34755474Hypercoagulability test strategies in the protein C and protein S pathway
Q37040260Hypercoagulable State
Q36254845Hypercoagulable states and stroke: a selective review.
Q36527933Hypercoagulable states and strokes
Q73454568Impact of activated protein C resistance on general vascular surgical patients
Q43631890Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study
Q54069752Incidence of factor V Leiden in patients with acute myocardial infarction.
Q57580952Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
Q44823539Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.
Q52995735Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.
Q57611907Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation
Q36318902Inherited prothrombotic states and ischaemic stroke in childhood
Q73374027Inherited risk factors for venous thromboembolism: Implications for clinical practice
Q33912473Inherited risk factors for venous thromboembolism: implications for clinical practice
Q73643174Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting
Q43015923Internal medical investigations for non-arteritic retinal artery occlusion
Q50749619Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
Q93149736Isolated pulmonary embolism in a patient with progestin intrauterine device and factor V Leiden
Q33181978Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease
Q77919943Laboratory evaluation of hypercoagulable states
Q37638524Late failure of a split-thickness skin graft in the setting of homozygous factor V Leiden mutation: a case report and correlative animal model from the Wound Etiology and Healing (WE-HEAL) study
Q52594205Latest Innovations in the Treatment of Venous Disease.
Q75211795Liver transplantation in a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation
Q33798485Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study
Q44870490MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population
Q77312905Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia
Q72000277Mutation in the Factor V Gene and the Risk of Myocardial Infarction
Q38760099Myocardial infarction and future risk of cancer in the general population-the Tromsø Study.
Q74079066Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C
Q34180939Myocardial infarction in patients with normal coronary arteries: proposed pathogenesis and predisposing risk factors
Q48985896Neonatal purpura fulminans in association with factor V R506Q mutation
Q73295920No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation
Q47820580No association between factor V Leiden mutation and coronary heart disease or carotid intima media thickness: the NHLBI Family Heart Study
Q71158541Nonconsensual participation in genetic studies
Q58491249Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS
Q77093727Oral contraceptives and arterial and venous thrombosis: a clinician's formulation
Q52951935Overestimation of genetic risks owing to small sample sizes in cardiovascular studies.
Q73073912PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
Q44073454Paradoxical embolism causing acute embolic events in a patient with hereditary thrombophilia
Q36954967Patent foramen ovale and hypercoagulability as combined risk factors for stroke
Q40813736Pediatric Thromboembolism in Japan
Q21144940Phased whole-genome genetic risk in a family quartet using a major allele reference sequence
Q36840306Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease
Q33635802Platelet-dependent and procoagulant mechanisms in arterial thrombosis.
Q39547196Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan
Q35085299Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis
Q34477685Polymorphisms in thrombophilia and renin-angiotensin system pathways, preterm delivery, and evidence of placental hemorrhage
Q70913456Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C
Q35692012Premature coronary artery disease: clinical risk factors and prognosis
Q90669073Prevalence and Outcomes of Thrombophilia in Patients with Acute Pulmonary Embolism
Q33739962Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts
Q35369291Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries
Q74315449Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction
Q34712722Prevalence of factor V Leiden in a Canadian blood donor population
Q33618227Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis
Q73276117Prevalence of three prothrombotic polymorphisms. Factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C 677T in Argentina. On behalf of the Grupo Cooperativo Argentino de Hemostasia y Trombosis
Q40838962Prevalence of thrombophilic disorders in takotsubo patients: the (ThROmbophylia in TAkotsubo cardiomyopathy) TROTA study
Q33857984Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors
Q22306369Primary prevention of ischemic stroke
Q28084640Progress in research into the genes associated with venous thromboembolism
Q46715240Prothrombin G20210A and factor V Leiden polymorphisms in stroke
Q47741045Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction
Q35113270Prothrombotic determinants of coronary atherothrombosis
Q28187014Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction
Q33347822Prothrombotic genetic risk factors and heparin-induced thrombocytopenia
Q77397081Prothrombotic mutations as a risk factor for preterm birth
Q71111882Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden
Q35691663Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
Q53929962Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.
Q36647304Recent trends in venous thrombosis and pulmonary embolism
Q36589500Recurrent pregnancy loss in a subject with heterozygote factor V Leiden mutation; a case report
Q38283515Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation
Q77357100Relative influence of age and thrombotic history on hemostatic parameters
Q41161249Resistance to activated protein C and a novel factor V gene mutation.
Q41714654Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease
Q77690865Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae
Q71094424Resistance to activated protein C in an unselected population of patients with pulmonary embolism
Q45882491Resistance to activated protein C in unselected patients with arterial and venous thrombosis
Q34013076Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease
Q73236487Risk factors for venous thromboembolism
Q36698661Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type
Q77742224Risk reduction in the intensive care unit
Q44556178Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion
Q77169209Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease
Q34573328Role of investigating thrombophilic disorders in young stroke.
Q58622092Résistance à la protéine C activée et thrombose portale: deux nouveaux cas et revue de la littérature
Q73886035Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion
Q54051918Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway.
Q74840852Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism
Q28222847Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration
Q33504430Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences.
Q54140056Stroke in a neonate heterozygous for factor V Leiden.
Q63544748Sudden Infant Death Syndrome, Childhood Thrombosis, and Presence of Genetic Risk Factors for Thrombosis
Q42089515Superior sagittal sinus and inferior vena cava thrombosis with acute Budd-Chiari syndrome
Q47913521The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns
Q52131991The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial.
Q35087733The Association of Coagulation Factor V (Leiden) and Factor II (Prothrombin) Mutations With Stroke
Q24794936The Ischemic Stroke Genetics Study (ISGS) Protocol
Q37186133The Obstetric Medicine Listserv: review of controversies surrounding thrombophilia testing
Q24803218The Siblings With Ischemic Stroke Study (SWISS) protocol
Q42919824The association of protein S Tokushima-K196E with a risk of deep vein thrombosis
Q74187715The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes
Q43598571The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease
Q73114776The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation
Q33685763The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood.
Q73485462The prevalence of two genetic traits related to venous thrombosis in whites and African-Americans
Q34971549Three periods of one and a half decade of ischemic stroke susceptibility gene research: lessons we have learned
Q35784744Thrombophilia Associated with Anti-DFS70 Autoantibodies
Q34043661Thrombophilia in pregnancy
Q33773160Thrombophilia-associated pregnancy wastage
Q33636714Thrombophilia: disorders predisposing to venous thromboembolism
Q77664583Thrombophilic disorders in children with cerebral infarction
Q90056535Treating Venous Thromboembolism Post Intracranial Hemorrhage: A Case Report
Q73851835Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis
Q36751693Vasa vitae--keeping the channels open
Q33950366Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.
Q47993392Venous thromboembolism hospitalizations among American Indians and Alaska Natives
Q54077386Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Q32151734Will genetics really revolutionize the drug discovery process?
Q34057587World distribution of factor V Leiden
Q70811527World distribution of factor V Leiden mutation
Q78006813[Angiology update]
Q81153272[Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature]
Q78724057[Cerebral-vein thrombosis: retrospective study of twenty seven cases]
Q79954729[Chronic abdominal pain due to bowel ischemia in a patient with Leiden factor V mutation]
Q74339763[Coronary thrombosis on patient with the factor V Leiden mutation]
Q78066774[Current suspect and diagnosis of pulmonary thromboembolism]
Q53919688[Factor V Leiden and myocardial infarction: a case, review of the literature with a meta-analysis].
Q79210246[Homocysteinemia and thrombophilic factors in unexplained decompression sickness]
Q74353796[New causes of inherited thrombophilia]

Search more.